Jean-Pierre E Antaki, MD
Infectious Disease · Glendale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 44 years
- Graduated 1982
Offices
1 location · Antaki and Associates Infectious Disease Medical Group Inc · 7 clinicians in this group
Looking this up.
Hospitals listed: Glendale Adventist Medical Center · Glendale Mem Hospital & Hlth Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Antaki’s office at (323) 242-5299 to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Glendale Adventist Medical CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.57) · 9,330 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.073, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.277, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Glendale Mem Hospital & Hlth CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.105, Oct 2024 – Sep 2025
See every measure and the patient survey for Glendale Adventist Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.57) · 9,330 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.073 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.277 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0.01 to 1.79) · 1,817 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.75 (0.48 to 1.01) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.81 (119.07 to 204.55) · 188 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 70 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 142 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 312 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.7 · 787 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 1,340 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 352 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,776 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 11,108 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.18 (0 to 0.35) · 11,736 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3 (1.22 to 4.78) · 2,564 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.76 (0.19 to 3.33) · 882 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.38 (0.04 to 2.71) · 2,540 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.3 (2.34 to 14.26) · 947 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.26 (1.99 to 8.53) · 895 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.94 (0.47 to 3.41) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 112 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.686 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.978 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.234 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.2 · 930 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30.6 · 370 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -4.5 · 1,036 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 30.9 · 1,549 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.9 · 1,397 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (7.5 to 15.5) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.9 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 68 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.5) · 183 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 416 cases | No different | Jan 2024 – Dec 2024 |
What patients said (759 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Glendale Mem Hospital & Hlth Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.105 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.49 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.55 (98.55 to 210.56) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 325 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.6 · 373 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,586 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,962 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,083 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.07 (0.76 to 5.38) · 734 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.29) · 196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 750 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.99 (0.29 to 17.7) · 201 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.34 (2.25 to 10.43) · 187 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.95) · 3,409 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.7 · 205 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.349 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.343 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.42 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.269 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 155 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -15.2 · 151 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.2 · 421 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.6 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 368 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.4 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 613 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 158 cases | No different | Jan 2024 – Dec 2024 |
What patients said (565 patients answered, 10% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$237,022
Medicare paid this office $237,022 for 944 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 601 | $113,660 | $89 |
| Transitional care management services for problem of at least moderate complexity | 96 | $34,293 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 311 | $31,907 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 279 | $28,621 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 118 | $16,053 | $128 |
See all 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 601 | $113,660 | $89 |
| Transitional care management services for problem of at least moderate complexity | 96 | $34,293 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 311 | $31,907 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 279 | $28,621 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 118 | $16,053 | $128 |
| Return visit (30+ min) | 53 | $7,527 | $65 |
| Long return visit (40+ min) | 22 | $2,941 | $105 |
Who their Medicare patients are
944 Original Medicare patients in 2024. Average age 78 · Under 65 11% · 85 and older 31% · Women 51% · Also on Medicaid 88% · Health risk score 3.55. Above the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Coronary heart disease 73% · Diabetes 71% · Heart failure 68% · Chronic kidney disease 60% · Depression 55% · COPD 51% · Atrial fibrillation 44% · Dementia 44% · Stroke 28% · Cancer 20%.
The office billed $663,795, Medicare allowed $305,544 and paid $237,022; for 2,622 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 944 | 2,622 | 78 | 3.55 | $663,795 | $237,022 |
| 2023 | 1,078 | 3,082 | 78 | 3.26 | $781,954 | $320,161 |
| 2022 | 1,141 | 3,982 | 78 | 2.88 | $1,011,217 | $404,897 |
| 2021 | 958 | 3,441 | 77 | 3.14 | $885,337 | $367,037 |
| 2020 | 1,216 | 4,546 | 78 | 3.28 | $1,143,961 | $456,170 |
| 2019 | 1,071 | 3,232 | 78 | 3.49 | $752,336 | $285,376 |
| 2018 | 1,084 | 3,393 | 78 | 3.31 | $715,887 | $303,582 |
| 2017 | 1,140 | 3,904 | 77 | 3.31 | $814,092 | $329,781 |
| 2016 | 986 | 3,757 | 76 | 3.35 | $761,799 | $316,711 |
| 2015 | 906 | 5,165 | 77 | 3.32 | $1,001,480 | $421,172 |
| 2014 | 794 | 4,663 | 76 | 3.05 | $892,148 | $373,882 |
| 2013 | 846 | 4,450 | 77 | 3.29 | $874,418 | $357,451 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 707 | $153,135 | $101 |
| Transitional care management services for problem of at least moderate complexity | 89 | $50,397 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 355 | $42,210 | $67 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 293 | $33,609 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 182 | $27,789 | $150 |
| Return visit (30+ min) | 60 | $11,233 | $77 |
2022: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 818 | $203,854 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 381 | $51,777 | $63 |
| Transitional care management services for problem of at least moderate complexity | 75 | $49,957 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 259 | $49,014 | $184 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 331 | $41,740 | $116 |
| Return visit (30+ min) | 46 | $6,944 | $83 |
| New patient visit (45+ min) | 11 | $1,146 | $104 |
2021: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 678 | $192,704 | $97 |
| Transitional care management services for problem of at least moderate complexity | 65 | $49,861 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 237 | $46,685 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 291 | $34,715 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 263 | $33,006 | $118 |
| Return visit (30+ min) | 53 | $7,292 | $78 |
| New patient visit (45+ min) | 11 | $1,243 | $113 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $836 | $33 |
2020: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 890 | $245,716 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 491 | $58,439 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 276 | $52,736 | $189 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 349 | $44,706 | $120 |
| Transitional care management services for problem of at least moderate complexity | 52 | $42,004 | $167 |
| Return visit (30+ min) | 57 | $6,458 | $65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $2,240 | $34 |
| Long return visit (40+ min) | 15 | $1,979 | $110 |
2019: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 665 | $135,379 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 358 | $42,293 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 379 | $37,825 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 177 | $30,120 | $165 |
| Return visit (30+ min) | 113 | $20,404 | $84 |
| Long return visit (40+ min) | 63 | $11,156 | $110 |
| New patient visit (60+ min) | 31 | $4,829 | $156 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $479 | $30 |
2018: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 664 | $141,938 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 442 | $49,386 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 412 | $49,081 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 176 | $30,721 | $170 |
| Return visit (30+ min) | 86 | $15,836 | $87 |
| Long return visit (40+ min) | 47 | $8,869 | $121 |
| New patient visit (60+ min) | 22 | $3,787 | $172 |
| New patient visit (45+ min) | 14 | $1,544 | $110 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 36 | $1,402 | $33 |
2017: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 741 | $159,567 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 483 | $57,801 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 485 | $55,810 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 191 | $31,808 | $162 |
| Return visit (30+ min) | 96 | $14,374 | $78 |
| Long return visit (40+ min) | 25 | $3,295 | $110 |
| New patient visit (60+ min) | 18 | $2,855 | $159 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 45 | $1,982 | $32 |
| Short return visit (20+ min) | 12 | $551 | $46 |
2016: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 654 | $144,731 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 468 | $64,714 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 451 | $55,335 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 157 | $26,702 | $168 |
| Return visit (30+ min) | 69 | $12,731 | $86 |
| Long return visit (40+ min) | 21 | $3,013 | $112 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 61 | $2,906 | $33 |
| New patient visit (45+ min) | 16 | $1,964 | $123 |
| New patient visit (60+ min) | 11 | $1,783 | $162 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,596 | $84 |
2015: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 660 | $208,071 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 563 | $105,529 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 559 | $70,631 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 98 | $16,638 | $170 |
| Return visit (30+ min) | 56 | $9,202 | $86 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 70 | $3,718 | $33 |
| Short return visit (20+ min) | 19 | $1,675 | $60 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,611 | $85 |
| Long return visit (40+ min) | 12 | $1,553 | $119 |
| New patient visit (45+ min) | 12 | $1,448 | $121 |
2014: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 595 | $175,966 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 473 | $103,172 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 498 | $62,209 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $12,055 | $170 |
| Return visit (30+ min) | 64 | $10,254 | $86 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 74 | $3,931 | $33 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,946 | $85 |
| Long return visit (40+ min) | 11 | $1,351 | $123 |
| Short return visit (20+ min) | 12 | $687 | $53 |
2013: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 629 | $185,125 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 461 | $75,893 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 417 | $49,337 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 117 | $19,468 | $164 |
| Return visit (30+ min) | 64 | $14,171 | $87 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 57 | $4,896 | $82 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 63 | $2,879 | $32 |
| New patient visit (45+ min) | 14 | $1,949 | $139 |
| Short return visit (20+ min) | 15 | $1,523 | $59 |
Medicaid work
$144,689 in 2024
Medicaid paid $144,689 for 5,981 billed services this clinician did in 2024, up to 110 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 2,547 | $65,442 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,202 | $40,462 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 597 | $20,085 |
| 1ST HOSP IP/OBS HIGH 75 | 202 | $7,848 |
| New patient visit (45+ min) | 99 | $4,143 |
| Long return visit (40+ min) | 132 | $3,456 |
| Return visit (30+ min) | 202 | $3,253 |
| 2024 | 5,981 | 7 | 110 | $144,689 |
| 2023 | 7,469 | 6 | 112 | $214,531 |
| 2022 | 6,449 | 5 | 110 | $157,955 |
| 2021 | 5,378 | 6 | 104 | $131,149 |
| 2020 | 4,877 | 7 | 88 | $115,842 |
| 2019 | 4,861 | 8 | 97 | $106,172 |
| 2018 | 5,095 | 7 | 91 | $83,930 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 3,535 | $102,025 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,475 | $58,310 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 692 | $29,796 |
| 1ST HOSP IP/OBS HIGH 75 | 381 | $17,561 |
| Return visit (30+ min) | 347 | $5,394 |
| New patient visit (45+ min) | 39 | $1,444 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 2,984 | $72,404 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,333 | $44,260 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 619 | $25,456 |
| 1ST HOSP IP/OBS HIGH 75 | 313 | $13,205 |
| Return visit (30+ min) | 200 | $2,630 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 3,123 | $76,007 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,519 | $29,006 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 364 | $13,267 |
| 1ST HOSP IP/OBS HIGH 75 | 235 | $10,275 |
| Return visit (30+ min) | 124 | $1,585 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 13 | $1,009 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 2,984 | $69,049 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,151 | $24,230 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 243 | $8,595 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 169 | $6,036 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 59 | $2,984 |
| 1ST HOSP IP/OBS HIGH 75 | 81 | $2,771 |
| Return visit (30+ min) | 190 | $2,177 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,114 | $45,649 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,600 | $34,152 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 403 | $14,882 |
| Return visit (30+ min) | 586 | $6,824 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 93 | $2,768 |
| New patient visit (45+ min) | 28 | $825 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 13 | $619 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 24 | $454 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,557 | $40,021 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,547 | $27,044 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 397 | $10,519 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 188 | $2,866 |
| Return visit (30+ min) | 380 | $2,800 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 13 | $405 |
| New patient visit (45+ min) | 13 | $276 |
Drugs they prescribed that Part D paid
$1,166,504
Pharmacies billed $1,166,504 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 876) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
502 generic and 374 brand-name prescriptions · $1,166,504 in drug cost · 230 antibiotic prescriptions to 103 people · 12 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 152 | $599,290 | $3,943 |
| Genvoya | 35 | $143,366 | $4,096 |
| Triumeq | 30 | $115,617 | $3,854 |
| Tivicay | 18 | $38,127 | $2,118 |
| Descovy | 18 | $37,196 | $2,066 |
See all 35 drugs
| Biktarvy | 152 | $599,290 | $3,943 |
| Genvoya | 35 | $143,366 | $4,096 |
| Triumeq | 30 | $115,617 | $3,854 |
| Tivicay | 18 | $38,127 | $2,118 |
| Descovy | 18 | $37,196 | $2,066 |
| Xifaxan | 12 | $36,752 | $3,063 |
| Isentress | 12 | $24,104 | $2,009 |
| Posaconazole | 20 | $22,867 | $1,143 |
| Vemlidy | 12 | $15,703 | $1,309 |
| Ertapenem | 16 | $6,975 | $436 |
| Efavirenz-Emtric-Tenofov Disop | 11 | $5,597 | $509 |
| Atazanavir Sulfate | 12 | $2,905 | $242 |
| Dexlansoprazole Dr | 12 | $2,730 | $228 |
| Itraconazole | 11 | $2,702 | $246 |
| Rifabutin | 11 | $1,828 | $166 |
| Ceftriaxone | 18 | $1,386 | $77 |
| Ritonavir | 12 | $795 | $66 |
| Valacyclovir | 25 | $789 | $32 |
| Ziprasidone | 12 | $710 | $59 |
| Albuterol Sulfate Hfa | 13 | $642 | $49 |
| Azithromycin | 18 | $411 | $23 |
| Ethambutol | 16 | $388 | $24 |
| Rifampin | 12 | $331 | $28 |
| Hydrocortisone | 11 | $268 | $24 |
| Fluconazole | 21 | $263 | $13 |
| Cefdinir | 29 | $249 | $9 |
| Doxycycline Hyclate | 16 | $229 | $14 |
| Acyclovir | 20 | $178 | $9 |
| Amoxicillin-Clavulanate Potass | 16 | $96 | $6 |
| Warfarin | 24 | $83 | $3 |
| Ciprofloxacin | 13 | $81 | $6 |
| Sulfamethoxazole-Trimethoprim | 19 | $62 | $3 |
| Latanoprost | 12 | $47 | $4 |
| Escitalopram | 12 | $26 | $2 |
| Amoxicillin | 11 | $15 | $1 |
Year by year
| 2024 | 876 | 154 | 0% (0) | 43% | $1,166,504 |
| 2023 | 904 | 167 | None | None | $1,118,065 |
| 2022 | 875 | 175 | 0% (0) | None | $972,602 |
| 2021 | 851 | 149 | 0% (0) | None | $913,101 |
| 2020 | 1,007 | 178 | None | 41% | $1,092,587 |
| 2019 | 1,161 | 222 | 2% (18) | 32% | $944,770 |
| 2018 | 1,147 | 209 | 1% (12) | 35% | $899,454 |
| 2017 | 1,091 | 238 | None | None | $952,647 |
| 2016 | 807 | 154 | 0% (0) | 41% | $689,811 |
| 2015 | 857 | 163 | None | 40% | $378,327 |
| 2014 | 743 | 135 | None | 45% | $381,066 |
| 2013 | 772 | 119 | None | 41% | $427,263 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Biktarvy | 110 | $463,621 | $4,215 |
| Genvoya | 55 | $229,513 | $4,173 |
| Triumeq | 29 | $105,560 | $3,640 |
| Xifaxan | 12 | $42,731 | $3,561 |
| Dovato | 11 | $29,602 | $2,691 |
| Posaconazole | 12 | $28,315 | $2,360 |
| Isentress | 13 | $26,729 | $2,056 |
| Vemlidy | 12 | $15,701 | $1,308 |
| Efavirenz-Emtric-Tenofov Disop | 12 | $13,703 | $1,142 |
| Ertapenem | 16 | $9,842 | $615 |
| Dexlansoprazole Dr | 12 | $5,144 | $429 |
| Ampicillin-Sulbactam | 45 | $4,156 | $92 |
| Atazanavir Sulfate | 12 | $4,018 | $335 |
| Cefepime | 17 | $3,232 | $190 |
| Rifampin | 25 | $2,331 | $93 |
| Valacyclovir | 17 | $1,765 | $104 |
| Doxycycline Hyclate | 21 | $1,035 | $49 |
| Ritonavir | 13 | $843 | $65 |
| Ziprasidone | 12 | $763 | $64 |
| Doxycycline Monohydrate | 12 | $722 | $60 |
| Albuterol Sulfate Hfa | 12 | $568 | $47 |
| Sulfamethoxazole-Trimethoprim | 26 | $564 | $22 |
| Fluconazole | 15 | $376 | $25 |
| Metronidazole | 22 | $353 | $16 |
| Acyclovir | 24 | $347 | $14 |
| Azithromycin | 13 | $341 | $26 |
| Cefdinir | 22 | $315 | $14 |
| Amoxicillin-Clavulanate Potass | 18 | $293 | $16 |
| Warfarin | 24 | $249 | $10 |
| Cephalexin | 22 | $229 | $10 |
| Latanoprost | 12 | $105 | $9 |
2022: 25 drugs
| Biktarvy | 95 | $365,085 | $3,843 |
| Genvoya | 54 | $207,544 | $3,843 |
| Noxafil | 12 | $59,980 | $4,998 |
| Triumeq | 16 | $55,933 | $3,496 |
| Xifaxan | 14 | $45,419 | $3,244 |
| Efavirenz-Emtric-Tenofov Disop | 18 | $21,283 | $1,182 |
| Efavirenz | 13 | $10,805 | $831 |
| Ceftriaxone | 37 | $9,085 | $246 |
| Abacavir | 13 | $5,647 | $434 |
| Vancomycin | 16 | $3,103 | $194 |
| Valacyclovir | 16 | $2,714 | $170 |
| Ziprasidone | 14 | $2,382 | $170 |
| Rifampin | 18 | $1,446 | $80 |
| Doxycycline Hyclate | 32 | $1,436 | $45 |
| Entecavir | 12 | $858 | $71 |
| Albuterol Sulfate Hfa | 12 | $568 | $47 |
| Cephalexin | 40 | $428 | $11 |
| Fluconazole | 12 | $359 | $30 |
| Azithromycin | 13 | $310 | $24 |
| Cefdinir | 18 | $281 | $16 |
| Metronidazole | 19 | $236 | $12 |
| Amoxicillin-Clavulanate Potass | 18 | $193 | $11 |
| Acyclovir | 18 | $134 | $7 |
| Ciprofloxacin | 11 | $53 | $5 |
| Latanoprost | 14 | $49 | $4 |
2021: 32 drugs
| Biktarvy | 90 | $317,253 | $3,525 |
| Genvoya | 64 | $225,475 | $3,523 |
| Noxafil | 18 | $110,714 | $6,151 |
| Triumeq | 12 | $40,788 | $3,399 |
| Xifaxan | 12 | $35,660 | $2,972 |
| Isentress | 19 | $34,952 | $1,840 |
| Efavirenz | 12 | $9,916 | $826 |
| Ertapenem | 15 | $8,415 | $561 |
| Dexilant | 11 | $7,318 | $665 |
| Janumet | 13 | $6,982 | $537 |
| Abacavir | 12 | $5,290 | $441 |
| Atazanavir Sulfate | 13 | $4,421 | $340 |
| Nevirapine | 13 | $4,298 | $331 |
| Ceftriaxone | 27 | $3,532 | $131 |
| Doxycycline Hyclate | 37 | $2,192 | $59 |
| Valacyclovir | 12 | $1,668 | $139 |
| Metronidazole | 31 | $903 | $29 |
| Ritonavir | 13 | $859 | $66 |
| Entecavir | 12 | $858 | $71 |
| Ventolin Hfa | 12 | $722 | $60 |
| Rosuvastatin | 13 | $503 | $39 |
| Ziprasidone | 13 | $367 | $28 |
| Cephalexin | 37 | $356 | $10 |
| Diclofenac | 12 | $308 | $26 |
| Acyclovir | 19 | $189 | $10 |
| Ibandronate | 13 | $144 | $11 |
| Triamcinolone Acetonide | 13 | $141 | $11 |
| Ciprofloxacin | 18 | $110 | $6 |
| Amoxicillin-Clavulanate Potass | 17 | $96 | $6 |
| Escitalopram | 13 | $91 | $7 |
| Carvedilol | 13 | $75 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $42 | $4 |
2020: 37 drugs
| Genvoya | 82 | $272,121 | $3,319 |
| Biktarvy | 66 | $232,708 | $3,526 |
| Noxafil | 18 | $114,108 | $6,339 |
| Triumeq | 19 | $72,718 | $3,827 |
| Atripla | 21 | $60,147 | $2,864 |
| Isentress | 34 | $59,217 | $1,742 |
| Xifaxan | 12 | $32,390 | $2,699 |
| Hepsera | 12 | $19,109 | $1,592 |
| Viread | 12 | $15,400 | $1,283 |
| Daptomycin | 11 | $15,215 | $1,383 |
| Ertapenem | 20 | $11,161 | $558 |
| Efavirenz | 13 | $10,743 | $826 |
| Dexilant | 13 | $7,687 | $591 |
| Janumet | 13 | $6,505 | $500 |
| Ceftriaxone | 41 | $6,069 | $148 |
| Abacavir | 13 | $5,849 | $450 |
| Atazanavir Sulfate | 13 | $2,693 | $207 |
| Cefazolin | 18 | $2,012 | $112 |
| Doxycycline Hyclate | 36 | $1,816 | $50 |
| Ziprasidone | 11 | $1,515 | $138 |
| Ritonavir | 13 | $1,098 | $84 |
| Entecavir | 13 | $919 | $71 |
| Ventolin Hfa | 13 | $766 | $59 |
| Metronidazole | 23 | $726 | $32 |
| Cephalexin | 55 | $433 | $8 |
| Ibandronate | 13 | $384 | $30 |
| Ciprofloxacin | 23 | $252 | $11 |
| Fluconazole | 12 | $248 | $21 |
| Acyclovir | 20 | $236 | $12 |
| Triamcinolone Acetonide | 13 | $141 | $11 |
| Amoxicillin-Clavulanate Potass | 18 | $140 | $8 |
| Nevirapine | 13 | $94 | $7 |
| Warfarin | 11 | $86 | $8 |
| Latanoprost | 11 | $84 | $8 |
| Rosuvastatin | 13 | $78 | $6 |
| Escitalopram | 11 | $49 | $4 |
| Carvedilol | 13 | $36 | $3 |
2019: 44 drugs
| Genvoya | 88 | $300,019 | $3,409 |
| Noxafil | 14 | $99,627 | $7,116 |
| Biktarvy | 28 | $87,704 | $3,132 |
| Stribild | 23 | $77,933 | $3,388 |
| Isentress | 38 | $60,797 | $1,600 |
| Atripla | 15 | $40,769 | $2,718 |
| Triumeq | 11 | $33,952 | $3,087 |
| Xifaxan | 12 | $28,479 | $2,373 |
| Hepsera | 11 | $16,523 | $1,502 |
| Voriconazole | 14 | $15,824 | $1,130 |
| Viread | 11 | $13,388 | $1,217 |
| Ertapenem | 19 | $13,322 | $701 |
| Ceftriaxone | 45 | $8,919 | $198 |
| Dexilant | 11 | $6,268 | $570 |
| Janumet | 12 | $5,477 | $456 |
| Vancomycin | 20 | $4,274 | $214 |
| Meropenem | 16 | $3,852 | $241 |
| Piperacillin-Tazobactam | 12 | $3,205 | $267 |
| Atazanavir Sulfate | 12 | $2,629 | $219 |
| Cefepime | 12 | $2,248 | $187 |
| Ziprasidone | 12 | $1,994 | $166 |
| Doxycycline Hyclate | 40 | $1,843 | $46 |
| Ritonavir | 12 | $890 | $74 |
| Ciprofloxacin | 44 | $833 | $19 |
| Rosuvastatin | 12 | $803 | $67 |
| Ventolin Hfa | 12 | $674 | $56 |
| Metronidazole | 27 | $628 | $23 |
| Ibandronate | 12 | $496 | $41 |
| Fluconazole | 15 | $431 | $29 |
| Cephalexin | 49 | $384 | $8 |
| Ethambutol | 13 | $358 | $28 |
| Azithromycin | 16 | $266 | $17 |
| Acyclovir | 17 | $245 | $14 |
| Amoxicillin-Clavulanate Potass | 23 | $235 | $10 |
| Warfarin | 20 | $141 | $7 |
| Nevirapine | 12 | $132 | $11 |
| Triamcinolone Acetonide | 12 | $122 | $10 |
| Tramadol | 18 | $106 | $6 |
| Sulfamethoxazole-Trimethoprim | 18 | $105 | $6 |
| Isoniazid | 12 | $74 | $6 |
| Latanoprost | 11 | $61 | $6 |
| Carvedilol | 12 | $42 | $4 |
| Gabapentin | 11 | $36 | $3 |
| Lorazepam | 11 | $25 | $2 |
2018: 36 drugs
| Genvoya | 57 | $171,362 | $3,006 |
| Stribild | 39 | $123,962 | $3,179 |
| Isentress | 62 | $95,143 | $1,535 |
| Truvada | 40 | $78,469 | $1,962 |
| Atripla | 21 | $57,647 | $2,745 |
| Triumeq | 12 | $35,960 | $2,997 |
| Invanz | 17 | $21,604 | $1,271 |
| Viread | 15 | $18,337 | $1,222 |
| Hepsera | 12 | $18,220 | $1,518 |
| Atazanavir Sulfate | 12 | $10,884 | $907 |
| Vancomycin | 36 | $10,002 | $278 |
| Entecavir | 15 | $9,594 | $640 |
| Voriconazole | 12 | $8,783 | $732 |
| Ritonavir | 16 | $7,272 | $455 |
| Meropenem | 26 | $5,894 | $227 |
| Nevirapine Er | 17 | $5,741 | $338 |
| Itraconazole | 19 | $4,724 | $249 |
| Abacavir | 11 | $4,703 | $428 |
| Ceftriaxone | 35 | $4,596 | $131 |
| Cefepime | 25 | $3,585 | $143 |
| Doxycycline Hyclate | 39 | $2,129 | $55 |
| Ampicillin-Sulbactam | 19 | $1,970 | $104 |
| Abacavir-Lamivudine | 13 | $1,428 | $110 |
| Valacyclovir | 17 | $1,017 | $60 |
| Cephalexin | 48 | $542 | $11 |
| Metronidazole | 20 | $538 | $27 |
| Acyclovir | 16 | $431 | $27 |
| Ciprofloxacin | 39 | $417 | $11 |
| Amoxicillin-Clavulanate Potass | 28 | $351 | $13 |
| Azithromycin | 16 | $302 | $19 |
| Nevirapine | 12 | $297 | $25 |
| Nitrofurantoin Mono-Macro | 11 | $213 | $19 |
| Atorvastatin | 20 | $160 | $8 |
| Sulfamethoxazole-Trimethoprim | 14 | $160 | $11 |
| Warfarin | 20 | $147 | $7 |
| Tramadol | 11 | $52 | $5 |
2017: 41 drugs
| Isentress | 83 | $125,420 | $1,511 |
| Truvada | 62 | $101,792 | $1,642 |
| Stribild | 18 | $55,131 | $3,063 |
| Triumeq | 12 | $33,483 | $2,790 |
| Complera | 11 | $28,991 | $2,636 |
| Invanz | 28 | $23,864 | $852 |
| Prezista | 13 | $22,238 | $1,711 |
| Reyataz | 13 | $20,352 | $1,566 |
| Selzentry | 12 | $18,033 | $1,503 |
| Viread | 15 | $17,208 | $1,147 |
| Hepsera | 12 | $15,691 | $1,308 |
| Entecavir | 16 | $14,589 | $912 |
| Norvir | 26 | $11,135 | $428 |
| Nevirapine Er | 17 | $7,378 | $434 |
| Emtriva | 12 | $6,416 | $535 |
| Vancomycin | 34 | $6,257 | $184 |
| Ampicillin-Sulbactam | 42 | $5,977 | $142 |
| Abacavir | 21 | $5,529 | $263 |
| Ceftriaxone | 42 | $4,831 | $115 |
| Piperacillin-Tazobactam | 24 | $4,817 | $201 |
| Abacavir-Lamivudine | 12 | $4,495 | $375 |
| Lamivudine | 21 | $2,064 | $98 |
| Doxycycline Hyclate | 37 | $1,283 | $35 |
| Valacyclovir | 20 | $1,094 | $55 |
| Ethambutol | 12 | $825 | $69 |
| Fluconazole | 24 | $816 | $34 |
| Metronidazole | 39 | $739 | $19 |
| Proair Hfa | 13 | $728 | $56 |
| Amoxicillin-Clavulanate Potass | 32 | $547 | $17 |
| Nevirapine | 13 | $537 | $41 |
| Acyclovir | 20 | $460 | $23 |
| Levofloxacin | 20 | $435 | $22 |
| Rifampin | 12 | $435 | $36 |
| Cephalexin | 45 | $397 | $9 |
| Sulfamethoxazole-Trimethoprim | 24 | $389 | $16 |
| Azithromycin | 11 | $172 | $16 |
| Doxycycline Monohydrate | 11 | $160 | $15 |
| Ciprofloxacin | 18 | $132 | $7 |
| Atorvastatin | 15 | $120 | $8 |
| Pantoprazole | 14 | $108 | $8 |
| Isoniazid | 14 | $92 | $7 |
2016: 29 drugs
| Isentress | 73 | $94,300 | $1,292 |
| Truvada | 60 | $89,040 | $1,484 |
| Atripla | 13 | $32,105 | $2,470 |
| Prezista | 16 | $20,689 | $1,293 |
| Viread | 17 | $16,936 | $996 |
| Reyataz | 12 | $16,294 | $1,358 |
| Hepsera | 12 | $14,830 | $1,236 |
| Entecavir | 14 | $13,253 | $947 |
| Norvir | 26 | $9,895 | $381 |
| Vancomycin | 33 | $9,541 | $289 |
| Nevirapine Er | 18 | $8,276 | $460 |
| Emtriva | 11 | $5,900 | $536 |
| Abacavir | 17 | $4,425 | $260 |
| Ceftriaxone | 13 | $3,068 | $236 |
| Meropenem | 11 | $2,459 | $224 |
| Doxycycline Hyclate | 33 | $2,056 | $62 |
| Ampicillin-Sulbactam | 22 | $1,746 | $79 |
| Lamivudine | 18 | $1,557 | $86 |
| Rifampin | 11 | $759 | $69 |
| Metronidazole | 28 | $704 | $25 |
| Proair Hfa | 12 | $639 | $53 |
| Amoxicillin-Clavulanate Potass | 25 | $549 | $22 |
| Nevirapine | 12 | $538 | $45 |
| Valacyclovir | 12 | $387 | $32 |
| Sodium Chloride | 14 | $341 | $24 |
| Acyclovir | 17 | $321 | $19 |
| Cephalexin | 22 | $300 | $14 |
| Sulfamethoxazole-Trimethoprim | 13 | $294 | $23 |
| Levofloxacin | 23 | $218 | $9 |
2015: 33 drugs
| Isentress | 60 | $72,998 | $1,217 |
| Truvada | 38 | $51,783 | $1,363 |
| Atripla | 18 | $40,327 | $2,240 |
| Viread | 29 | $27,287 | $941 |
| Prezista | 20 | $20,232 | $1,012 |
| Epzicom | 13 | $15,418 | $1,186 |
| Reyataz | 12 | $15,301 | $1,275 |
| Hepsera | 12 | $14,021 | $1,168 |
| Entecavir | 14 | $12,980 | $927 |
| Norvir | 24 | $9,321 | $388 |
| Invanz | 15 | $8,779 | $585 |
| Abacavir | 13 | $3,758 | $289 |
| Ampicillin-Sulbactam | 42 | $3,499 | $83 |
| Vancomycin | 24 | $2,449 | $102 |
| Ceftriaxone | 20 | $2,445 | $122 |
| Doxycycline Hyclate | 25 | $2,249 | $90 |
| Sodium Chloride | 24 | $2,020 | $84 |
| Lamivudine | 13 | $1,523 | $117 |
| Fluconazole | 13 | $921 | $71 |
| Metronidazole | 28 | $795 | $28 |
| Ethambutol | 12 | $709 | $59 |
| Cefazolin | 11 | $644 | $59 |
| Proair Hfa | 12 | $610 | $51 |
| Valacyclovir | 15 | $451 | $30 |
| Nevirapine | 12 | $427 | $36 |
| Amoxicillin-Clavulanate Potass | 28 | $339 | $12 |
| Acyclovir | 20 | $278 | $14 |
| Azithromycin | 18 | $248 | $14 |
| Sulfamethoxazole-Trimethoprim | 26 | $230 | $9 |
| Levofloxacin | 27 | $201 | $7 |
| Famotidine | 17 | $176 | $10 |
| Cephalexin | 25 | $149 | $6 |
| Ciprofloxacin | 14 | $115 | $8 |
2014: 32 drugs
| Truvada | 46 | $62,738 | $1,364 |
| Isentress | 41 | $51,359 | $1,253 |
| Atripla | 22 | $46,079 | $2,095 |
| Prezista | 28 | $28,448 | $1,016 |
| Viread | 29 | $25,719 | $887 |
| Baraclude | 13 | $15,686 | $1,207 |
| Reyataz | 13 | $15,574 | $1,198 |
| Hepsera | 12 | $13,601 | $1,133 |
| Selzentry | 11 | $12,793 | $1,163 |
| Norvir | 31 | $11,320 | $365 |
| Viramune Xr | 12 | $7,781 | $648 |
| Emtriva | 13 | $6,674 | $513 |
| Piperacillin-Tazobactam | 14 | $4,164 | $297 |
| Vancomycin | 18 | $3,838 | $213 |
| Ampicillin-Sulbactam | 17 | $2,472 | $145 |
| Imipenem-Cilastatin | 15 | $1,301 | $87 |
| Azithromycin | 19 | $910 | $48 |
| Ethambutol | 13 | $798 | $61 |
| Fluconazole | 13 | $770 | $59 |
| Proair Hfa | 13 | $641 | $49 |
| Amox Tr-Potassium Clavulanate | 26 | $626 | $24 |
| Valacyclovir | 12 | $565 | $47 |
| Sulfamethoxazole-Trimethoprim | 34 | $513 | $15 |
| Metronidazole | 28 | $507 | $18 |
| Nevirapine | 13 | $470 | $36 |
| Acyclovir | 16 | $444 | $28 |
| Ciprofloxacin | 22 | $248 | $11 |
| Levofloxacin | 15 | $145 | $10 |
| Cephalexin | 17 | $137 | $8 |
| Alprazolam | 12 | $58 | $5 |
| Famotidine | 11 | $55 | $5 |
| Trazodone | 11 | $55 | $5 |
2013: 31 drugs
| Voriconazole | 30 | $88,260 | $2,942 |
| Isentress | 41 | $54,969 | $1,341 |
| Atripla | 25 | $48,804 | $1,952 |
| Truvada | 31 | $48,188 | $1,554 |
| Viread | 32 | $27,250 | $852 |
| Reyataz | 16 | $17,865 | $1,117 |
| Prezista | 14 | $14,980 | $1,070 |
| Hepsera | 13 | $13,986 | $1,076 |
| Baraclude | 13 | $13,474 | $1,036 |
| Norvir | 33 | $12,625 | $383 |
| Viramune Xr | 12 | $7,306 | $609 |
| Abacavir | 13 | $6,645 | $511 |
| Ceftriaxone | 23 | $5,784 | $251 |
| Emtriva | 11 | $5,378 | $489 |
| Ampicillin-Sulbactam | 28 | $2,786 | $99 |
| Azithromycin | 21 | $2,672 | $127 |
| Lamivudine | 14 | $2,604 | $186 |
| Cefazolin | 11 | $2,323 | $211 |
| Ethambutol | 22 | $2,155 | $98 |
| Rifampin | 12 | $1,059 | $88 |
| Amox Tr-Potassium Clavulanate | 22 | $582 | $26 |
| Proair Hfa | 12 | $561 | $47 |
| Nevirapine | 12 | $545 | $45 |
| Ciprofloxacin | 26 | $362 | $14 |
| Acyclovir | 21 | $353 | $17 |
| Sulfamethoxazole-Trimethoprim | 37 | $315 | $9 |
| Metronidazole | 13 | $258 | $20 |
| Cephalexin | 21 | $247 | $12 |
| Levofloxacin | 11 | $184 | $17 |
| Isoniazid | 11 | $63 | $6 |
| Trazodone | 11 | $55 | $5 |
Money from drug and device companies
$601 in 2025
| 2025 | 5 | 26 | None | $601 |
| 2024 | 5 | 28 | None | $561 |
| 2023 | 6 | 24 | None | $513 |
| 2022 | 4 | 24 | None | $425 |
| 2021 | 4 | 20 | None | $242 |
| 2020 | 2 | 4 | None | $63 |
| 2019 | 3 | 22 | None | $256 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Avycaz | $215 | 11 payments
|
| Gilead Sciences | None | $208 | 8 payments
|
| Shionogi | Fetroja | $80 | 3 payments
|
| Merck Sharp & Dohme | Pifeltro | $77 | 3 payments
|
| ViiV Healthcare | Apretude | $20 | 1 payment
|
See all 26 published payments
| Merck Sharp & Dohme | Meals · 2025-12-09 | None | $24 |
| Abbvie | Meals · 2025-11-20 | Emblaveo | $21 |
| Gilead Sciences | Meals · 2025-11-04 | None | $28 |
| Abbvie | Meals · 2025-10-28 | Emblaveo | $33 |
| Merck Sharp & Dohme | Meals · 2025-09-11 | Zerbaxa | $24 |
| Abbvie | Meals · 2025-09-04 | Emblaveo | $26 |
| Gilead Sciences | Meals · 2025-08-28 | None | $30 |
| ViiV Healthcare | Meals · 2025-08-04 | Apretude | $20 |
| Shionogi | Meals · 2025-07-24 | Fetroja | $23 |
| Gilead Sciences | Meals · 2025-07-22 | None | $33 |
| Gilead Sciences | Meals · 2025-06-26 | None | $28 |
| Abbvie | Meals · 2025-06-23 | Emblaveo | $6 |
| Abbvie | Meals · 2025-06-13 | Avycaz | $19 |
| Shionogi | Meals · 2025-06-12 | Fetroja | $32 |
| Gilead Sciences | Meals · 2025-06-05 | None | $7 |
| Abbvie | Meals · 2025-05-08 | Avycaz | $29 |
| Shionogi | Meals · 2025-04-24 | Fetroja | $25 |
| Abbvie | Meals · 2025-04-15 | Avycaz | $33 |
| Gilead Sciences | Meals · 2025-04-10 | None | $30 |
| Abbvie | Meals · 2025-04-08 | Avycaz | $12 |
| Gilead Sciences | Meals · 2025-03-25 | None | $22 |
| Abbvie | Meals · 2025-03-04 | Avycaz | $16 |
| Abbvie | Meals · 2025-01-28 | Avycaz | $11 |
| Abbvie | Meals · 2025-01-23 | Avycaz | $9 |
| Gilead Sciences | Meals · 2025-01-21 | None | $31 |
| Merck Sharp & Dohme | Meals · 2025-01-16 | Pifeltro | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $561
| Abbvie | Avycaz | $213 | 16 payments
|
| Gilead Sciences | None | $173 | 6 payments
|
| Astellas Pharma US | Cresemba | $99 | 3 payments
|
| Shionogi | Fetroja | $48 | 2 payments
|
| ViiV Healthcare | Apretude | $29 | 1 payment
|
2023: $513
| Astellas Pharma US | Cresemba | $175 | 3 payments
|
| AbbVie | Avycaz | $170 | 14 payments
|
| Gilead Sciences | None | $102 | 4 payments
|
| Insmed | Arikayce | $26 | 1 payment
|
| Paratek Pharmaceuticals | Nuzyra | $21 | 1 payment
|
| Merck Sharp & Dohme | Pifeltro | $20 | 1 payment
|
2022: $425
| Abbvie | Avycaz | $175 | 12 payments
|
| Gilead Sciences | None | $134 | 7 payments
|
| ViiV Healthcare | Dovato | $73 | 3 payments
|
| Shionogi | Fetroja | $43 | 2 payments
|
2021: $242
| AbbVie | Dalvance | $149 | 15 payments
|
| Merck Sharp & Dohme | Pifeltro | $35 | 2 payments
|
| Gilead Sciences | None | $30 | 1 payment
|
| Insmed | Arikayce | $28 | 2 payments
|
2020: $63
| Allergan | Avycaz | $32 | 2 payments
|
| Merck Sharp & Dohme | Zerbaxa | $31 | 2 payments
|
2019: $256
| Merck Sharp & Dohme | Isentress | $195 | 19 payments
|
| ViiV Healthcare | Juluca | $45 | 2 payments
|
| Allergan | Avycaz | $16 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| RedHill Biopharma Inc. · Study of Rhb-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (Mac) Disease in Adults With Nodular Bronchiectasis (Clear-Mac Trial) · 2023 | Their institution | $6,000 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 56.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013972876
- Licence
- CA F13854
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 801 S Chevy Chase Dr, #105, Glendale, CA, 91205
- NPI first listed
- 2006-04-17
- NPI last updated
- 2026-07-13
This is when the NPI record was last certified, not a medical board exam.